Parallel Advisors, LLC
Position in PTGX — Protagonist Therapeutics, Inc
CIK 1690010
SAN FRANCISCO, CA
Position in PTGX
as of Jun 30, 2026
· filed Aug 5, 2026
Position Value
$14,464
+$1,500 QoQ
Shares Held
118
-4.1% QoQ
Ownership
0.000%
of shares outstanding
% of Portfolio
0.00%
of 13F equity value
Holder Rank
#294
of 341 holders
Holding Since
Jun 2024
9 quarters on record
Voting authority
Sole 0%
Shared 0%
None 100%
Common Shares in PTGX Over Time
Shares Held
Position Value (USD)
Position in Biotechnology
Healthcare · as of Jun 30, 2026Parallel Advisors, LLC holds $359,916,636 across 168 Biotechnology names. PTGX ranks #70 (0.0% of the industry book) .
| # | Ticker | Company | Shares | Value (USD) | Open |
|---|---|---|---|---|---|
| 1 | CORT |
Corcept Therapeutics Inc
|
3,962,177 | $344,511,290 | |
| 2 | VRTX |
Vertex Pharmaceuticals Inc / Ma
|
5,389 | $2,676,877 | |
| 3 | RCUS |
Arcus Biosciences, Inc.
|
86,557 | $2,668,552 | |
| 4 | REGN |
Regeneron Pharmaceuticals, Inc.
|
1,063 | $662,823 | |
| 5 | KRYS |
Krystal Biotech, Inc.
|
1,699 | $631,467 | |
| 6 | ARGX |
Argenx SE
|
640 | $593,772 | |
| 7 | INCY |
Incyte Corp
|
4,961 | $562,378 | |
| 8 | VKTX |
Viking Therapeutics, Inc.
|
13,833 | $539,625 |
All Filings in PTGX
Export CSV
9 filing rows on record
| Report Date | Value (USD) | Shares | Type | Discretion | Filed | |
|---|---|---|---|---|---|---|
| 2026-06-30 | $14,464 | 118 | Shares | Sole | 2026-08-05 | |
| 2026-03-31 | $12,964 | 123 | Shares | Sole | 2026-05-07 | |
| 2025-12-31 | $9,520 | 109 | Shares | Sole | 2026-02-11 | |
| 2025-09-30 | $6,775 | 102 | Shares | Sole | 2025-11-13 | |
| 2025-06-30 | $5,361 | 97 | Shares | Sole | 2025-07-08 | |
| 2025-03-31 | $1,305 | 27 | Shares | Sole | 2025-04-08 | |
| 2024-12-31 | $1,042 | 27 | Shares | Sole | 2025-02-10 | |
| 2024-09-30 | $1,935 | 43 | Shares | Sole | 2024-11-13 | |
| 2024-06-30 | $935 | 27 | Shares | Sole | 2024-08-08 | |
| No filing history on record for this holder in this stock. | ||||||